This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Health Stocks in Motion

Updated from 3:33 p.m. EDT

Shares of Gentiva Health Services (GTIV) were among the worst-performing health-related stocks Thursday, falling 16.4% after the company posted first-quarter earnings and sales that disappointed Wall Street.

The provider of home health services posted earnings of $4.1 million, or 17 cents a share, on sales of $207.1 million. Analysts surveyed by Thomson First Call were expecting earnings of 21 cents a share on sales of $217.8 million. A year ago the company reported adjusted earnings of $4.3 million, or 16 cents a share, on sales of $205.9 million, which excludes special items.

Looking ahead, Gentiva now expects 2005 earnings of 75 cents to 83 cents a share, up from previous guidance of 72 cents to 80 cents a share. Part of the company's upward revision is due to a delay in the implementation of accounting rules on stock-based compensation, which will now go into affect during fiscal 2006, instead of the second half of 2005. The accounting change would have increased expenses by 6 cents to 8 cents a share.

The company also said that its outlook is based on the acquisition of Heritage Home Care Services, a conservative view regarding sales from its Cigna relationship -- based on first-quarter results -- and the company's decision to invest in clinical capacity and branch operations. Gentiva backed its 2005 sales estimate of $870 million to $890 million. Analysts are expecting earnings of 83 cents a share on sales of $893 million. Shares traded down $3.42 to $17.41.

Bentley Pharmaceuticals (BNT) rose 22.6% after the company posted first-quarter results that easily topped expectations. The drug delivery company earned $2.2 million, or 10 cents a share, on sales of $24.2 million. Analysts were expecting earnings of 5 cents a share on sales of $20.1 million. Results were helped by sales volume growth in Spain, a strengthening of the euro against the dollar and continued growth in pharmaceutical sales to licensees, both in Spain and outside of Spain. A year ago the company earned $800,000, or 4 cents a share, on sales of $17.3 million. Shares traded up $1.71 to $9.29.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
TWTI $20.35 -0.92%
GTIV $19.19 -1.18%
MRK $58.18 -0.68%
SMA $9.27 -0.43%
SCLN $7.78 -0.13%


DOW 18,217.75 -70.88 -0.39%
S&P 500 2,105.30 -12.09 -0.57%
NASDAQ 4,976.19 -31.9060 -0.64%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs